Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02088567 · ClinicalTrials.gov registry record · NA

Amniotic Membrane in Total Knee Replacements to Reduce Scarring

A NA study of Scarring, sponsored by MiMedx Group.

Completed
Registry status
NA
Development phase
52
Enrollment target
1
Study location

NCT02088567 is a NA study of Scarring that has completed, run by MiMedx Group. The registered enrollment target is 52 participants, below the 77-participant average among 8 other Scarring trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02088567, a NA study of Scarring, has completed, sponsored by MiMedx Group.

COMPLETED
Registry status
NA
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

The overall objective of this study is to evaluate the effectiveness of dHACM in reducing scar tissue formation in total knee replacement patients.

Conditions Studied

Interventions

  • PROCEDURE Total Knee Arthroplasty
  • OTHER Application of dHACM

Study Locations (1)

Georgia

  • Georgia Knee and Sports Medicine - Decatur

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2014-01
Est. Completion 2014-10
Phase NA

Sponsor

MiMedx Group

32 total trials

What the Registry Record Tells You About NCT02088567

The ClinicalTrials.gov registry entry for NCT02088567 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 77-participant average among 8 other Scarring trials with a reported enrollment target (32% lower). The listed sponsor is MiMedx Group, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Scarring appearing as the primary indexed condition, and to 2 interventions - of which Total Knee Arthroplasty is the first listed.

NCT02088567 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT02088567 about?

NCT02088567 is a clinical study titled "Amniotic Membrane in Total Knee Replacements to Reduce Scarring". The overall objective of this study is to evaluate the effectiveness of dHACM in reducing scar tissue formation in total knee replacement patients.

What is the current status of trial NCT02088567?

This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2014-01. Estimated completion is 2014-10.

What conditions does trial NCT02088567 study?

This clinical trial studies the following conditions: Scarring.

What interventions are being tested in trial NCT02088567?

The interventions under investigation include: Total Knee Arthroplasty (PROCEDURE), Application of dHACM (OTHER).

Who is sponsoring clinical trial NCT02088567?

This trial is sponsored by MiMedx Group, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02088567 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Scarring

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.